News Archive

Duke Clinical Research Institute builds a lasting tradition around celebrating milestone moments

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti

A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.

The latest cohort of young researchers got a head start on learning the skills necessary to build a future in research over the summer, as they completed the Duke STAR program in August, 2022.

Following the recent organizational changes at Twitter and concerns about how they may affect the platform, DCRI Chief Science & Digital Officer Eric Perakslis, PhD, offers insights for clinicians and researchers who use the platform to share their work.

From the main stage, presenting late-breaking science to poster presentations and breakout sessions, Duke Clinical Research Institute faculty and fellows were prominently featured throughout the 20

Less complex heart patients may benefit, but not without risk

A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.

In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the